Yim H - Search Results

1

Oligopeptide Competition Assay for Phosphorylation Site Determination.

Joo MS, Koo JH, Shin SB, Yim H, Kim SG. Joo MS, et al. Among authors: yim h. J Vis Exp. 2017 May 18;(123):55708. doi: 10.3791/55708. J Vis Exp. 2017. PMID: 28570513 Free PMC article.

2

Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.

Shin SB, Woo SU, Yim H. Shin SB, et al. Among authors: yim h. J Cell Physiol. 2015 Dec;230(12):3057-67. doi: 10.1002/jcp.25042. J Cell Physiol. 2015. PMID: 25975351

3

Sensitivity of TP53-Mutated Cancer Cells to the Phytoestrogen Genistein Is Associated With Direct Inhibition of Plk1 Activity.

Shin SB, Woo SU, Chin YW, Jang YJ, Yim H. Shin SB, et al. Among authors: yim h. J Cell Physiol. 2017 Oct;232(10):2818-2828. doi: 10.1002/jcp.25680. Epub 2017 Apr 10. J Cell Physiol. 2017. PMID: 27861885

4

Comparative Analysis of a FRET-based PLK1 Kinase Assay to Identify PLK1 inhibitors for Chemotherapy.

Shin SB, Woo SU, Lee YJ, Yim H. Shin SB, et al. Among authors: yim h. Anticancer Res. 2017 Mar;37(3):1177-1183. doi: 10.21873/anticanres.11431. Anticancer Res. 2017. PMID: 28314279

5

Nrf2-lncRNA controls cell fate by modulating p53-dependent Nrf2 activation as an miRNA sponge for Plk2 and p21^cip1.

Joo MS, Shin SB, Kim EJ, Koo JH, Yim H, Kim SG. Joo MS, et al. Among authors: yim h. FASEB J. 2019 Jul;33(7):7953-7969. doi: 10.1096/fj.201802744R. Epub 2019 Mar 21. FASEB J. 2019. PMID: 30897343

-Joo, M. S., Shin, S.-B., Kim, E. J., Koo, J. H., Yim, H., Kim, S. G. Nrf2-lncRNA controls cell fate by modulating p53-dependent Nrf2 activation as an miRNA sponge for Plk2 and p21(cip1)....

-Joo, M. S., Shin, S.-B., Kim, E. J., Koo, J. H., Yim, H., Kim, S. G. Nrf2-lncRNA controls cell fate by modulating p53- …

6

Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer.

Shin SB, Woo SU, Yim H. Shin SB, et al. Among authors: yim h. Ther Adv Med Oncol. 2019 May 8;11:1758835919846375. doi: 10.1177/1758835919846375. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31156720 Free PMC article.

7

Active PLK1-driven metastasis is amplified by TGF-β signaling that forms a positive feedback loop in non-small cell lung cancer.

Shin SB, Jang HR, Xu R, Won JY, Yim H. Shin SB, et al. Among authors: yim h. Oncogene. 2020 Jan;39(4):767-785. doi: 10.1038/s41388-019-1023-z. Epub 2019 Sep 23. Oncogene. 2020. PMID: 31548612 Free PMC article.

8

Correction: Active PLK1-driven metastasis is amplified by TGF-β signaling that forms a positive feedback loop in non-small cell lung cancer.

Shin SB, Jang HR, Xu R, Won JY, Yim H. Shin SB, et al. Among authors: yim h. Oncogene. 2020 Jan;39(4):951. doi: 10.1038/s41388-019-1049-2. Oncogene. 2020. PMID: 31595031 Free PMC article.

9

Combination of Inhibitors of USP7 and PLK1 has a Strong Synergism against Paclitaxel Resistance.

Shin SB, Kim CH, Jang HR, Yim H. Shin SB, et al. Among authors: yim h. Int J Mol Sci. 2020 Nov 16;21(22):8629. doi: 10.3390/ijms21228629. Int J Mol Sci. 2020. PMID: 33207738 Free PMC article.

10

PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma.

Jang HR, Shin SB, Kim CH, Won JY, Xu R, Kim DE, Yim H. Jang HR, et al. Among authors: yim h. Cell Death Differ. 2021 Sep;28(9):2745-2764. doi: 10.1038/s41418-021-00781-4. Epub 2021 May 7. Cell Death Differ. 2021. PMID: 33963314 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,114 results

Search Page

Filters